Prestige Consumer Healthcare (PBH) Asset Writedowns and Impairment (2018 - 2023)
Prestige Consumer Healthcare (PBH) posted quarterly Asset Writedowns and Impairment of $369.8 million for Q1 2023, up 34882.97% year-over-year from N/an in Q1 2022, and up 36976900.0% quarter-over-quarter from $1000.0 in Q3 2022.
Prestige Consumer Healthcare (PBH) Asset Writedowns and Impairment (2018 - 2023) Analysis & Trends
Prestige Consumer Healthcare's Asset Writedowns and Impairment history runs 6 years deep, the most recent figure standing at $369.8 million for Q1 2023.
- In Q1 2023, Asset Writedowns and Impairment rose 34882.97% year-over-year to $369.8 million; the TTM figure through Sep 2023 stood at $369.8 million (up 24485.77% YoY), while the FY2025 annual figure was $12.5 million, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q1 2023 stood at $369.8 million, up from $1000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $369.8 million in Q1 2023, with the low at -$34000.0 in Q1 2020.
- The 5-year median for Asset Writedowns and Impairment is $446000.0 (2022), against an average of $54.8 million.
- The sharpest annual moves came in 2020 and 2023: Asset Writedowns and Impairment plunged 100.01% in 2020, then soared 34882.97% in 2023.
- Prestige Consumer Healthcare's Asset Writedowns and Impairment stood at $34000.0 in 2019, then soared by 2335.29% to $828000.0 in 2020, then surged by 80.8% to $1.5 million in 2021, then sank by 99.93% to $1000.0 in 2022, then jumped by 36976900.0% to $369.8 million in 2023.
- Business Quant data shows PBH's Asset Writedowns and Impairment at $369.8 million in Q1 2023, $1000.0 in Q3 2022, and $446000.0 in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Prestige Consumer Healthcare | 2.46 Bn | 2.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 369.77 Mn |
| Mar 31, 2023 | 369.77 Mn |
| Sep 30, 2022 | 1,000.00 |
| Sep 30, 2022 | 1,000.00 |
| Jun 30, 2022 | 446,000.00 |
| Jun 30, 2022 | 446,000.00 |
| Mar 31, 2022 | 1.06 Mn |
| Mar 31, 2022 | 1.06 Mn |
| Mar 31, 2021 | 1.50 Mn |
| Mar 31, 2021 | 1.50 Mn |
| Dec 31, 2020 | 828,000.00 |
| Dec 31, 2020 | 828,000.00 |
| Sep 30, 2020 | 59,000.00 |
| Sep 30, 2020 | 59,000.00 |
| Jun 30, 2020 | 50,000.00 |
| Jun 30, 2020 | 50,000.00 |
| Mar 31, 2020 | -34,000.00 |
| Mar 31, 2020 | -34,000.00 |
| Dec 31, 2019 | 34,000.00 |
| Dec 31, 2019 | 34,000.00 |